Revolution Medicines to Participate in TD Cowen 4th Annual Oncology Innovation Summit

May 24, 2023

REDWOOD CITY, Calif., May 24, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced that Mark A. Goldsmith, M.D., Ph.D., the company's chief executive officer and chairman, will be a featured speaker in a fireside chat at the TD Cowen 4th Annual Oncology Innovation Summit.

Details of the company's participation are as follows:

- **TD Cowen 4th Annual Oncology Innovation Summit**
  Conference Dates: May 30-31, 2023
  Fireside Chat Time/Date: 12:30 p.m. Eastern on Wednesday, May 31, 2023
  Location: Virtual conference; webcast available

To access the live webcast of the fireside chat, please visit the "Events & Presentations" page of Revolution Medicines' website at https://ir.revmed.com/events-and-presentations. Additionally, a replay of the webcast will be available on the "Events & Presentations" page of the Revolution Medicines website for at least 14 days following the conference.

About Revolution Medicines, Inc.

Revolution Medicines is a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) Inhibitors designed to suppress diverse oncogenic variants of RAS proteins, and RAS Companion Inhibitors for use in combination treatment strategies. The company's RAS(ON) Inhibitors RMC-6236 (RAS^{MULTI}) and RMC-6291($KRAS^{G12C}$) are currently in clinical development. Additional RAS(ON) Inhibitors in the company's pipeline include RMC-9805 ($KRAS^{G12D}$) and RMC-0708 ($KRAS^{Q61H}$), both of which are currently in IND-enabling development, RMC-8839 ($KRAS^{G13C}$), and additional compounds targeting other RAS variants. RAS Companion Inhibitors in clinical development include RMC-4630 (SHP2) and RMC-5552 (mTORC1/4EBP1).

Contact: For Investors & Media: Erin Graves 650-779-0136 egraves@revmed.com